Biology of gut cholecystokinin and gastrin receptors

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 3-4, 1997, Pages 209-216

  Shulkes, Arthur ^a,b   Baldwin, Graham S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Austin Campus ^*  (Australia)

Author keywords

Cholecystokinin; Cholecystokinin receptors; Gastrin; Gastrin receptors

Indexed keywords

CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; GASTRIN RECEPTOR;

DRUG RECEPTOR BINDING; GALLBLADDER; HUMAN; PANCREAS; REVIEW; STOMACH;

EID: 0030903562     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb01809.x     Document Type: Review

References (98)

1. Dockray GJ. Regulatory peptides and the neuroendocrinology of gut-brain relations. Q. J. Exp. Physiol. 1988; 73: 703-27.
2. Wank SA. Cholecystokinin receptors. Am. J. Physiol. 1995; 269: G628-46.
3. Silvente-Poirot S, Dufresne M, Vaysse N, Fourmy D. The peripheral cholecystokinin receptors. Enr. J. Biochem. 1993; 215: 513-29.
4. Liddle RA. Cholecystokinin. In: Walsh JH, Dockray GJ (eds). Cut Peplules: Biochemistry and Physiology. Raven Press, New York. 1994; Ch. 7.
5. Walsh JH. Gastrin. In: Walsh JH, Dockray GJ (eds). Gut Peptides: Biochemistry and Physiology. Raven Press, New York.. 1994; Ch. 4.
6. Monstein HJ, Thorup JU, Folkesson R, Johnsen AH, Rehfeld JE cDNA deduced procionin. Structure and expression in protochordates resemble thatofprocholecystokinin in mammals. FEES Lett. 1993; 331:60-4.
7. Dimaline R, Dockray GJ. Evolution of the gastrointestinal endocrine system (with special reference to gastrin and CCK). Bailliére's Clin. Endocrinol. Metab. 1994; 8: 1-24.
8. Vigna SR, Thomdyke MC, Williams JA. Evidence for a common evolutionary origin of brain and pancreas cholecystokinin receptors. Proc. NatlAcad. Sei. USA 1986; 83: 4355-9.
9. Oliver AS, Vigna SR. CCK-X receptors in the endothermic mako shark ([sums oxyrinchus). Gen. Comp. Endocrinol. 1996; 102: 61-73.
10. Lloyd KCK. Gut hormones in gastric function. Bailliére's Clin. Endocrinol. Metab. 1994; 8: 111-36.
11. Hersey S, Sachs G. Gastric acid secretion. Physiol. Rev. 1995; 75: 155-89.
12. Prinz C, Scott DR, Hurwitz D, Heiander HF, Sachs G. Gastrin effects on isolated rat enterochromaffin-like cells in primary culture. Am. J. Physiol. 1994; 267: G663-75.
13. Calam J. Helicobacter pylori. Eur. J. Clin. Invest. 1994; 24: 501-10.
14. Hakanson R, Blom H, Carlsson E, Larsson H, Ryberg B, Sundler F. Hypergastrinaemia produces trophic effects in stomach but not in pancreas and intestines. Regul. Pept. 1986; 13: 225-33.
15. Baldwin GS. The role of gastrin and cholecystokinin in normal and neoplastic gastrointestinal growth. J. Gastiventeivl. Hepatol. 1995; 10:215-32.
16. Rehfeld JF, van Solinge WV. The tumor biology of gastrin and cholecystokinin. Adv. Cancer Res. 1994; 63: 295-347.
17. Dockray GJ, Varro A, Dimaline R. Gastric endocrine cells: Gene expression, processing, and targeting of active products. Physiol. Rev. 1996; 76: 767-98.
18. Varro A, Voronina S, Dockray GJ. Pathways of processing of the gastrin precursor in rat antral mucosa. J. din. Invest. 1995; 95: 1642-9.
19. Lamers CB, Walsh JH, Jansen JB, Harrison AR, Ippoliti AF, Van Tongeren JH. Evidence that gastrin34 is preferentially released from the human duodenum. Gastroenterology 1982; 82: 233-9.
20. Eysselein VE, Maxwell V, Reedy T, Wunsch E, Walsh JH. Similar acid stimulatory potencies of synthetic human big and little gastrins in man. J. Clin. Invest. 1984; 73: 1284-90.
21. Hilsted L, Hansen CP. Corelease of amidated and glycine-extended antral gastrin after a meal. Am. J. Physiol. 1988; 255: G665-9.
22. Delvalle J, Sugano K, Yamada T. Glycine-extended processing intermediates of gastrin and cholecystokinin in human plasma. Gastroenterology 1989; 97: 2259-63.
23. Hilsted L. Glycine-extended gastrin precursors. Regul. Pept. 1991; 36:323-13.
24. Ciccotosoto GD, McLeish A, Hardy KJ, Shulkes A. Expression, processing and secretion of gastrin in patients with colorectal carcinoma. Gastroenlerohgy 1995; 109: 1142-53.
25. Van Solinge WW, Neilsen FC, Fris-Hansen L, Falkmer U, Rehfeld JF. Expression but incomplete processing of progastrin in colorectal carcinomas. Gastroenterology 1993; 104: 1099-107.
26. +-ATPase a-subunit gene expression through a novel receptor. J. Biol. Chem. 1995; 270: 11 155-60.
27. Higashide S, Gomez G, Greeley, GH Jr, Townsend CM Jr, Thompson JC. Glycine-extended gastrin potentiates gastrin stimulated gastric acid secretion in rats. Am. J. Physiol. 1996; 270: G220-4.
28. Seva C, Dickinson CJ, Yamada T. Grow th-promoting effects of glycineextended progaslrin. Science 1994; 265: 410-12.
29. Singh P, Ovvlia A, Espeijo R, Dai B. Novel gastrin receptors mediate mitogenic effects of gastrin and processing intermediates of gastrin on Swiss 3T3 fibroblasts. J. Biol. Chem. 1995; 270: 8429-38.
30. Freston JW, Borch K, Brand SJ et al. Effects of hypochorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis. Dig. Dis. Sei. 1995; 40 (Suppl. 2): S50-62.
31. Dickinson CJ. Relationship of gastrin processing to colon cancer. Gastmenterology 1995; 109: 1384-8.
32. Rehfeld JF. Gastrin and colorectal cancer: A never ending dispute? Gastroenterology 1995; 108: 1307-9.
33. Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides 1994; 15: 731-55.
34. Liddle RA. Regulation of cholecystokinin secretion by intraluminal releasing factors. Am. J. Pliysiol. 1995; 269: G319-27.
35. Raybould HE, Lloyd KC. Integration of postprandial function in the proximal gastrointestinal tract. Role of CCK and sensory pathways. Ann. N.Y.Acad.Sci. 1994; 713: 143-56.
36. Schwanz GJ, Moran TH. CCK elicits and modulates vagal afferent activity arising from gastric and duodenal sites. Ann. N.Y. Acad. Sei. 1994; 713: 121-8.
37. Shulkes A. Somatostatin: Physiology and clinical applications. Bailliére's Clin. Endocrinol. Metab. 1994; 8: 215-36.
38. Soil AH, Amirian DA, Park J, Elashoff JD, YamadaT. Cholecystokinin potently releases Somatostatin from canine fundic mucosal cells in shortterm culture. Am. J. Physiol. 1985; 248: G569-73.
39. Konturek JW, Konturek SJ, Domsche W. Role of cholecystokinin in the control of gastric acid secretion and gastrin release in dogs and healthy and duodenal ulcer subjects. Scand. J. Gaslroenterol. 1993; 28: 657-60.
40. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Satiety effects of a physiological dose of cholecystokinin in humans. Gut 1995; 36: 176-9.
41. Stephens TW, Basinski M, Bristow PK etal. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995; 377: 530-2.
42. Lamers CB, Jansen JB, Woutersen RA. Cholecystokinin and gastrointestinal cancer. J. Steroid Biochem. Mol. Dial. 1990; 37: 1069-72.
43. Axelsen J, Ihse I, Hakanson R. Pancreatic cancer: The role of cholecystokinin? Scand. J. Gaslroenterol. 1992; 27: 993-8.
44. Yu D-H, Huang SC, Wank SA, Mantey S, Gardner JD, Jensen RT. Pancreatic receptors for cholecystokinin: Evidence for three receptor classes. Am. J. Physiol. 1990; 258: G86-95.
45. Talkad VD, Fortune KP, Polio DA, Shah GN, Wank SA, Gardner JD. Direct demonstration of three different states of the pancreatic cholecystokinin receptor. Proc. Nail Acad. Sei. USA 1994; 91: 1868-72.
46. Huang S-C, Fortune KP, Wank SA, Kopin AS, Gardner JD. Multiple affinity states of different cholecystokinin receptors. J. Biol. Client. 1994; 269: 26 121-6.
47. Hahne WF, Jensen RT, Lemp GF, Gardner JD. Proglumide and benzotript: Members of a different class of cholecystokinin receptor antagonists. Proc. NatlAcad. Sei. USA 198I; 78: 6304-8.
48. Chang RSL, Lotti VJ, Monaghan RL et al. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergilltts alliaceus. Science 1985; 230: 177-9.
49. Chang RSL, Lotti VJ. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc. Nail Acad. Sei. USA 1986; 83: 4923-6.
50. Lotti VJ, Chang RSL. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365 260. Eur. J. Pliarmacol. 1989; 162: 273-80.
51. Weinstock J, Baldwin GS. Binding of gastrinn to human gastric carcinoma cell lines. Cancer Res. 1988; 48: 932-7.
52. Hoosein NM, Kiener PA, Curry RC, Rovati LC, McGilbra DK, Brattain MG. Antiproliferative effects of gastrin receptor antagonists and antibodies to gastrin on human colon carcinoma cell lines. Cancer Res. 1988; 48:7179-83.
53. Baldwin GS. Binding of progastrin fragments to the 78 kDa gastrinbinding protein. FEBS Lett. 1995; 359: 97-100.
54. Baldwin GS. Antiproliferative gastrin/cholecystokinin receptor antagonists target the 78 kDa gastrin-binding protein. Proc. NatlAcad. Sei. USA 1994; 91: 7593-7.
55. Baldwin GS. Gastrin receptor structure. In: Walsh JH (ed.). Gastrin. Raven Press, New York. 1993; Ch. 16.
56. Pearson RK, Miller LJ. Affinity labeling of a novel cholecystokininbinding protein in rat pancreatic plasmalemma using new short probes for the receptor. J. Biol. Client. 1987; 262: 869-76.
57. Pearson RK, Miller LJ, Hadac EM, Powers SP. Analysis of the carbohydrate composition of the pancreatic plasmalemmal glycoprotein affinity labeled by short probes for the cholecystokinin receptor. J. Biol.Chem. 1987; 262: 13850-6.
58. Matsumoto M, Park J, Yarnada T. Gastrin receptor characterization: Affinity cross-linking of the gastrin receptor on canine gastric parietal cells. Am. J. Physiol. 1987; 252: G143-7.
59. Duong LT, Hadac EM, Miller LJ, Vlasuk GP. Purification and characterization of the rat pancreatic cholecystokinin receptor. J. Biol. Chem. 1989; 264: 17 990-6.
60. Kopin AS, Lee Y-M, McBride EW el al. Expression cloning and characterization of canine parietal cell gastrin receptor. Proc, NatlAcad. Sei. USA 1992; 89: 3605-9.
61. Wank SA, Harkins R, Jensen RT, Shapira H, De Weerth A, Slattery T. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc. NatlAcad. Sei. USA 1992; 89:3125-9.
62. Strader CD, Fong TM, Tola MR, Underwood D. Structure and function of G-protein-coupled receptors. Annu. Rev. Biochem. 1994; 63: 101-32.
63. Beinborn M, Lee Y-M, McBride EW, Quinn SM, Kopin AS. A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature 1993; 362: 348-50.
64. Mantamadiotis T, Baldwin GS. The seventh transmembrane domain of gastrin/CCK receptors contributes to non-peptide antagonist binding. Biochem. Biopliys. Res. Commun. I994; 201: 1382-9.
65. Kopin AS, McBride EW, Quinn SM, Kolakowski LF Jr, Beinbom M. The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands. J. Biol. Chem. 1995;270:5019-23.
66. Kennedy K, Escrieut C, Dufresne M, Clerc P, Vaysse N, Fourmy D. Identification of a region of the N-terminal of the human CCKA receptor essential for the high affinity interaction with agonist CCK. Biochem Biopliys. Res. Commun. 1995; 213: 845-52.
67. Silvente-Poirot A, Escrieut C, Dufresne M, Martinez J, Bouisson M, Vaysse C, Fourmy D. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor. A/0J. Pltarm. 1994; 45: 599-607.
68. Miyaké A. A truncated isoform of human CCK-B/gastrin receptor generated by alternative usage of a novel exon. Biochem. Biopliys. Res. Commun. 1995; 208: 230-7.
69. Song I, Brown DR, Wiltshire RN, Gantz I, Trent JM, Yamada T. The human gastrin/cholecystokinin type B receptor gene: Alternative splice donor site in exon 4 generates two variant mRNAs. Proc. Natl Acad. Sei. USA 1993; 90: 9085-9.
70. Miller LJ, Holicky EL, Ulrich CD, Wieben ED. Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. Gastroenterology 1995; 109: 1375-80.
71. Funakoshi A, Miyasaka K, Shinozaki H, Masuda M, Kawanami T, Takata Y, Kono A. An animal model of congenital defect of gene expression of cholecystokinin (CCK)-A receptor. Biochem. Biopliys. Res. Commun. 1995; 210: 787-96.
72. Klueppelberg UG, Gates LK, Gorelick FS, Miller LJ. Agonist-regulated phosphorylation of the pancreatic cholecystokinin receptor. J. Biol. Chem. 1991;266:2403-8.
73. Ozcelebi F, Miller LJ. Phosphopeptide mapping of cholecystokinin receptors on agonist-stimulated native pancreatic acinar cells. J. Biol. Cite in. 1995:270:3435-41.
74. Gates LK, Ulrich CD, Miller LJ. Multiple kinases phosphorylate the pancreatic cholecystokinin receptor in an agonist-dependent manner. Am. J. Physiol. 1993; 264: G840-7.
75. Lutz MP, Pinon DI, Gates LK, ShenolikarS, Miller LJ. Control of cholecystokinin receptor dephosphory lation in pancreatic acinar cells. J. Biol. Chem. 1993; 268: 12 136-42.
76. Williams JA, Blevins GT Jr. Cholecystokinin and regulation of pancreatic acinar cell function. Physiol. Rev. 1993; 73: 701-23.
77. Chew CS, Nakamura K, Ljungslrorri M. Calcium signaling mechanisms in the gastric parietal cell.Tote J. Biol. Med. 1992; 65: 561-76.
78. 2+ and elevation of intracellular triphosphate by secretagogues in parietal and chief cells isolated from rabbit gastric mucosa. Biochim. Biopliys. Acta 1986; 888: 116-25.
79. Chiba T, Fisher SK, Park J, Seguin EB, Agranoff BW, Yamada T. Carbamoylcholine and gastrin induce inositol lipid turnover in canine gastric parietal cells. Am. J. Physiol. 1988; 255: G99-G105.
80. Roche S, Ball J-P, Magous R. Involvement of a pertussis toxinsensitive G protein in the action of gastrin on gastric parietal cells. Biochim. Biophys. Ada 1990; 1055: 287-94.
81. 2+ mobilization and clonal growth in small cell lung cancer cells. Cancer Res. 1992; 52: 6031-5.
82. 2+ mobilization and clonal growth. Cancer Res. 1993; 53: 5208-13.
83. MAP Oncogene 1994; 9: 861-7.
84. raf-1 kinase and mitogenesis. Cell Growth Differen. 1995; 6: 383-93.
85. Todisco A, Takeuchi Y, Seva C, Dickinson CJ, Yamada T. Gastrin and glycine-extended progastrin processing intermediates induce different programs of early gene activation. J. Biol. Client. 1995; 270:28 337-41.
86. Ulrich CD, Ferber I, Holicky E, Hada E, Buell G, Miller LJ. Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. Biochem. Biophys. Res. Commun. 1993; 193: 204-11.
87. Pisegna JR, de Weerth A, Huppi K, Wank SA. Molecular cloning of the human brain and gastric cholecystokinin receptor: Structure, functional expression and chromosomal localization. Biochem. Biophys. Res. Commun. 1992; 189: 296-303.
88. Chang RSL, Lotti VJ, Chen TB, Kunkel KA. Characterization of the binding of [ H]-(+)-L-364 718: A new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Mol. Phannacol. 1986; 30: 212-17.
89. Lee YM, Beinbom M, McBride EW, Lu M, Kolakowski LF, Kopin AS. The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J. Biol. Client. 1993; 268: 8164-9.
90. Lin CW, Holladay MW, Barrett RW et al. Direct requirements of activation at CCK-A and CCK-B/gastrin receptors: Studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33). Mol. Phannacol. 1989; 36: 881-6.
91. Lin CW, Holladay MW, Witte DG et al. A71378: A CCK agonist with high potency and selectivity for CCK-A receptors. Am. J. Physiol. 1990; 258: G648-51.
92. Witte DG, Nadzan AM, Martinez J, Rodriguez M, Lin CW. Characterization of the novel CCK analogs JMV-180, JMV-320 and JMV-332 in H345 cells. Peptides 1992; 13: 1227-32.
93. Boden PR, Higginbottom M, Hill DR et al. Cholecystokinin dipeptoid antagonists: Design, synthesis and anxiolytic profile of some novel CCK-A and CCK-B selective and 'mixed' CCK-A/CCK-B antagonists. J. Med. Client. 1993; 36: 552-65.
94. Gully D, Fréhel D, Marcy C et al. Peripheral biological activity of SR 27897: A new potent non-peptide antagonist of CCKA receptors. Eur. J. Phannacol. 1993; 232: 13-19.
95. Hughes J, Boden P, Costall B et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc. NallAcad. Sei. USA 1990; 87: 6728-32.
96. Blommaert AGS, Weng J-H, Dorville A et al. Cholecystokinin peptidomimetics as selective CCK-B antagonists: Design, synthesis and in vitro and in vivo biochemical properties. J. Med Chem. 1993; 36:2868-77.
97. Pendley CE, Fitzpatrick LR, Capolino AJ et al. RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat.y. Phannacol. Exp. Tlier. 1995; 273: 1015-22.
98. + mobilization in a pituitary cell line. Eur. J. Pharmacol. 1992; 221: 99-105.